Showing 1731-1740 of 2065 results for "".
- Merix Pharmaceutical Corp: Releev Cold Sore Treatment Now in Convenience Storeshttps://practicaldermatology.com/news/merit-pharmaceutical-corp-releev-cold-sore-treatment-now-in-convenience-stores/2457644/Merix Pharmaceutical Corp’s Releev®1 Day Cold Sore Symptom Treatment is now available in convenience stores, including 7-Eleven and soon in Circle K in the United States. Releev
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://practicaldermatology.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2457649/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an
- FDA Approves Poteligeo for Cutaneous T-Cell Lymphomashttps://practicaldermatology.com/news/fda-approves-poteligeo-for-cutaneous-t-cell-lymphomas/2457657/The FDA approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with two types of cutaneous T-cell lymphoma (CTCL)—relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This a
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Ta
- Bonti's Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgeryhttps://practicaldermatology.com/news/bontis-novel-neurotoxin-shines-in-early-study-of-scar-reduction-after-mohs-surgery/2457662/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- Castle Biosciences' DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence, Metastasishttps://practicaldermatology.com/news/castle-biosciences-decisiondx-melanoma-test-improved-ajcc-based-risk-prediction-for-melanoma-recurrence-metastasis/2457664/Castle Biosciences, Inc’s. DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging, according to a new study presented at the DERM2018 NP/PA CME Conference held in Las Veg
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o
- Survey: Most Women Think Their Hands Make Them Look Oldhttps://practicaldermatology.com/news/survey-most-women-think-their-hands-make-them-look-old/2457674/Just shy of 80 percent of women ages 40 and older wish they could change the way their hands look, according to Nestlé Skin Health’s 'Face Your Hands' survey. Additionally, 60 percent reported they have actually taken step
- Núria Perez-Cullell Appointed CEO of Pierre Fabre Dermo-Cosmeticshttps://practicaldermatology.com/news/nria-perez-cullell-appointed-ceo-of-pierre-fabre-dermo-cosmetics/2457679/Ms. Núria PerezCullell is the new CEO of The Pierre Fabre Group’s Pierre Fabre Dermo-Cosmetics (PFDC) subsidiary. This appointment will take effect on August 20, 2018. Núria Perez-Cullell will take over from Mr. Eric Ducournau, whose appointment to the position of Pier